<DOC>
	<DOC>NCT00116740</DOC>
	<brief_summary>This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity. The purpose of this study is to obtain a preliminary assessment of the safety and efficacy of APD356, when administered daily for 12 weeks, in obese subjects who are otherwise healthy. Subjects who are on concomitant medications for control of hypertension or blood lipids may qualify.</brief_summary>
	<brief_title>Safety and Efficacy of APD356 in the Treatment of Obesity</brief_title>
	<detailed_description>This is a double-blind, placebo-controlled, randomized, parallel group study. Three different doses of APD356 or placebo will be administered daily for 12 weeks, to obese, male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects will be enrolled.</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Healthy male or nonpregnant, nonlactating females aged 1865 years (inclusive) Body mass index (BMI) of 3045 kg/m2 Nonsmoker No concomitant medications other than hypertension medications (stable &gt; 90 days) and/or statins (stable &gt; 90 days) No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency No more than mild mitral valve regurgitation and absence of aortic valve regurgitation upon screening echocardiogram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Serotonin</keyword>
	<keyword>5-HT2c</keyword>
	<keyword>Satiety</keyword>
	<keyword>Obesity</keyword>
	<keyword>Appetite suppressant</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Overweight</keyword>
</DOC>